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There´s are starman waiting in the sky 
	
He´d like to come and meet us 
	
But he thinks he´d blow our minds 
There´s a starman waiting in the sky 
He told us not to blow it 
Cause he knows it´s all worthwhile 
	
He told me: 
	
Let the children lose it 
	
Let the children use it 
	
Let all the children boogie 
	
	
	
	
David Bowie 
ABSTRACT 
	
Background: Before the era of combination therapy (c-ART) more than 90 % of the 
patients with HIV-infection died of one or more opportunistic infections (OI). We and 
others noted early on that CMV was an important pathogen in these patients. We 
investigated the OIs related to causes of death in all Venhälsan patients, with these specific 
questions 1) All OIs and opportunistic cancers (OC)s in patients who died with CD4+ 
counts below 100 x 106/mL;  2) The prevalence of CMV encephalitis (CMV-E) and 
Korsakoff syndrome (Paper 1);  3) CMV retinitis (CMV-R) in relation to CMV-E (Paper 
II); 4) CMV adrenalitis (CMV-A) and its relation to CMV-R and CMV-E, including 
comparison of CMV assessment by PCR in blood and the Synacthen test; 5) The 
correlation between CMV disease and other OIs and OCs (Papers I, II and III); 6) The 
interaction between CMV, Epstein Barr virus (EBV) and other human herpes viruses in a 
case of anaplastic large cell lymphoma (ALCL) (Paper IV) 
Material end methods: We followed all patients that died at Venhälsan from 1989-1996, 
with intensive blood testing, biopsies, culturing, X-ray, computer tomography CT, 
magnetic resonance imaging MRI as well as autopsy when permission was provided. We 
focused especially on Synacthen tests to diagnose CMV-A, neurological examinations to 
diagnose CMV-E and Korsakoff, and ophthalmologic examinations to diagnose CMV-R. In 
a case of anaplastic large cell lymphoma, we did extensive analysis of all human herpes 
viruses in the course of the disease. 
Results: Of all 219 patients, that died with CD4+ < 100 x 106/mL 87% showed signs of 
reactivated CMV-infection.  CMV-R was found in 84, CMV-E in 65, CMV-A in 41 and 
CMV in the gastrointestinal tract in 21. Mycobacterial infection was found in 87 and 
toxoplasmosis in 29. Kaposi’s sarcoma was the most common tumour (68 cases) followed 
by 22 patients with malignant lymphoma and 20 with CNS-lymphoma. CMV-reactivation 
was seen in most diagnostic. A case of primary CMV-infection leading to a malignant 
lymphoma by interaction with two other herpes viruses was also seen. 
Conclusion: CMV-infection was the main OI in AIDS-patients during the pre-c-ART era 
and also the main cause of death by itself or together with other OIs. Reactivation of CMV 
was found in 87%. The most important CMV manifestations were CMV-R, CMV-E and 
CMV-A that seemed to occur at the same time. All of them have characteristic symptoms. 
Thus, when one of these is diagnosed investigation for the other two should be done.  This 
is still today important in patients with CD4+ < 100 x 106/mL without access to modern 
HIV-treatment. These findings reveal the intimate interaction between HIV and CMV 
which should be considered in all co-infected patients also today. 
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1 INTRODUCTION 
	
1.1.1 HIV infection 
	
The first cases of what would later become known as Human Immunodeficiency Virus (HIV) 
infection were described in the Centers for Disease Control’s (CDC) Morbidity and Mortality 
Weekly Report in June 1982 (1). The disease occurred in clusters of homosexual males in 
New York, Los Angeles and San Francisco. Many had Kaposi´s sarcoma (a rare tumour in 
high-income countries at the time). Several had also had Pneumocystis carinii pneumonia 
(PCP), an opportunistic infection known to infect patients with lymphatic leukaemia and 
immunosuppressed bone marrow-transplant patients.(2-4) A few months later, Masur et al 
found that all these apparently previously healthy patients had signs of a compromised 
immune system. (5)The same infections were subsequently discovered in Haitians and 
haemophiliacs and an increasing number of papers on different opportunistic infections (OI) 
in these patients appeared during the following years (5-9) (Pneumocystis carinii has since 
been renamed pneumocystis jirovecii (10) but the term in use during the investigation period 
will be used in this thesis). 
	
1.1.2 Effect on the immune system and decrease in CD4+ count 
	
At the time, research concerning differentiation of human leukocytes was developing rapidly 
and labelling with antibodies led to the discovery of OKT3 cells, later named CD4+ cells. (9, 
11) It was very early revealed, that the patients with the new immune deficiency had low and 
decreasing CD4+ counts. The term AIDS (Acquired Immune Deficiency Syndrome), used to 
denote the disease, was established in September 1982 by CDC. The virus that caused the 
disease was described by Barre Sanoussi et al already in 1983 (12). Both the term HIV and 
the HIV infection were confirmed at the 2nd World AIDS conference in Paris in 1986. 
	
Today it is well established that the HIV-1 virus was transferred to humans from 
	
chimpanzees, while HIV-2, which is less pathogenic, derived from macaques (13). The HIV- 
	
1 epidemic originally followed the route from Africa, via Haiti, to the USA, as well as 
	
directly from Africa to Europe described by Pepin (13) and confirmed by Worobey et al (14) 
	
	
1.1.3 HIV treatment 
	
From 1982 to 1986, it was only the OIs in AIDS patients that could be treated. Zidovudin 
(AZT), a nucleoside analogue, was introduced in 1986; it was very effective in patients with 
HIV dementia as first described by (15) and then confirmed by Portegies (16). This drug also 
led to improved quality of life and weight gain, as well as decreased mortality and frequency 
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of OIs as summarized by Fischl et al (17). The HIV infection, however, usually progressed 
after a year with more OIs and related deaths. The effect of AZT on HIV dementia seemed to 
persist after more nucleoside analogues were introduced in 1991-1994, and it was discovered 
that combination therapy had a better effect on the disease. In 1996, a new combined 
antiretroviral treatment (ART) was introduced with dramatic effects on the quality and life 
expectancy of AIDS patients. This combination included a new drug class, the protease 
inhibitors (PI). HIV infects T-cells, especially CD4+ cells, dendritic cells, macrophages and 
microglia of the brain. It has several effects on the immune system; the killing of CD4+ T- 
cells (CD4+ cells) is a direct effect on the cellular immunity function and activation of B- 
cells producing antibodies that can interfere with body antigens, leading to autoimmunity.(18) 
Many of these B-cells do not produce effective antibodies against microbes, as seen in a 
deficient vaccine response study (Amu et al)(19). These defects in B-cells also influence the 
function of T-cells. Finally, even in patients undergoing successful ART treatment, there is a 
massive killing of CD4+ cells in the lymph glands (i.e. pyroptosis) described by Doitsh et al 
and Munoz-Aries et al (20, 21)leading to release of cytokines producing a chronic 
inflammatory reaction that can drive arteriosclerosis and cancer development. 
	
1.1.4 CMV infection 
	
Cytomegalovirus (CMV) is a beta-herpes virus that replicates in almost all cell types, such as 
blood cells, epithelial and endothelial cells and hepatocytes. The typical inclusion bodies seen 
in nuclei of CMV-infected cells were first described in 1881 by Ribbert. (22) A viral agent 
was suspected to cause these changes. The term Cytomegalia was used for the first time by 
Goodpasture and Gilbert in 1921. Mother-to-child transmission in utero was described in 
1950(18). Three different research groups originally isolated CMV strains in 1956. In 1960, 
the name CMV was proposed by Weller, who also isolated the virus from the urine of 
children with general CMV disease. Since then, many different detection methods have been 
developed. It also became apparent that CMV is an important pathogen in mother-to-child 
transmission and in patients with immunodeficiency. Organs that can be infected with CMV s 
include: Multiple infection of ductal epithelial cells such as salivary gland, gastrointestinal 
tract and epithelial cells of the inner ear, Eyes (retina), brain and peripheral nerves, pancreas, 
adrenal glands kidney, lung and thyroid glands 
	
CMV infection is ubiquitous and occurs in many animals, including primates. The oldest 
known CMV discovered is an oyster CMV believed to be 500 million years old. A 
phylogenetic tree of alfa, beta and gamma herpes viruses from (McGeoch et al)(23, 24) is 
shown in Figure 1 
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Figure 1. 
	
	
 
	
	
The phylogenetic tree shows the relationship between alpha-, beta- and gamma- herpes 
viruses in different species. The names of human herpes viruses are in bold. 
	
In humans, CMV is transmitted from 50% of infected mothers to their babies in connection 
with breastfeeding. After infancy, the virus is transmitted by kissing among teenagers (CMV 
accounts for 10% of clinical mononucleosis cases). The infection rate gradually increases 
during adulthood, leading to 70-80% eventually being infected with the virus. In certain 
groups, such as gay men with HIV infection, more than 95 % are infected. Children do not 
have serious symptoms of CMV infection if they are not infected during pregnancy; however, 
congenital infection can lead to serious encephalitis with severe sequelae. After infection, 
CMV remains latent, usually in blood cells. The virus usually does not cause any problems 
except in cases of immune deficiency, related for instance to chemotherapy, especially for 
lymphoma and leukaemia(25), or therapy associated with bone marrow or solid organ 
transplantation. (26-30). The lymphocyte antibody therapies used for malignancies and 
autoimmune diseases also cause severe immunosuppression (29, 31). Especially antibodies 
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against T-cells can generate an immunodeficiency similar to that in advanced HIV infection. 
It can also be a problem in patients ill with critical burns.(32-34). 
	
1.1.5 HIV and CMV co-infection 
	
In HIV-patients CMV emerged as a major pathogen, it was already described in the first 
reports as a possible cause of the new immune deficiency (2, 3) and during the following 
years numerous reports on CMV-disease was published (35-46). Interaction between HIV 
and CMV was discussed in some of the papers and CMV has also been reported to influence 
the natural history of HIV-infection (47). The main focus during this period was on CMV- 
Retinitis (CMV-R) that was the easiest to diagnose (36, 48-51) but many case reports and 
autopsy studies have also been published on CMV-encephalitis (CMV-E)(7, 35, 37, 40, 52) 
CMV-polyneuropathy (53) and CMV-colitis (54, 55). Case reports on CMV-adrenalitis 
(CMV-A) has been published as well as autopsy studies (56-61). But no cohort studies or 
other studies trying to get a full overview of the development of CMV-infection in these 
patients had been published. 
	
After the introduction of c-ART in 1996-7 the incidence of CMV-disease has decreased. One 
reason is the rapid restoration of CMV specific CD4+ cells (62). However, CMV-disease is 
still an important issue in low income countries (63-66). In recent years Freeman et al, has 
published a paper on CD8 cell expansion and inflammation linked to CMV- co-infection in 
patients with well controlled HIV-infection (67, 68) a sign that CMV-infection might still 
contribute to morbidity in HIV-infected patients. Ndumbi et al have found that delay in ART 
treatment results in persistent immune defects for many years especially if the patient initiate 
treatment with CD+ counts < 200x 106/mL (69). Gianella et al has found that replication of 
human herpes viruses, especially CMV is associated with higher HIV DNA levels during 
ART treatment. (70-73). They also found that replication of CMV in semen is associated 
with higher HIV-DNA levels (72, 74). A study by Lichtner et al of more than 6000 patients 
with HIV-infection has also shown that CMV-co-infection is associated with an increased 
risk of severe Non-AIDS defining events (75). 
	
	
1.1.6 Development of diagnostic methods  for HIV and CMV 
	
1.1.7 HIV 
	
During the period 1985-1996, serology was used to diagnose and confirm the HIV infection. 
HIV antigen determination was also used and the syncytium-forming properties of the HIV 
virus were also studied. Rapid-high versus slow-low replication of HIV can determine 
affinity for CXCR4 or CCR5 receptors. However, these properties of the virus have not been 
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included in this thesis, as preliminary data had shown CXCR4-reactive virus in 90% of AIDS 
patients that had been previously treated (76). Detection of viral HIV-RNA in serum/blood 
became available in 1996. We started to perform HIV-PCR diagnosis during the second half 
of 1996. 
	
1.1.8 CMV 
	
Serology in blood, the pp65 antigen test, virus isolation, rapid antigen assays, CMV-PCR in 
whole blood with ethylene diamine tetra acetic acid (EDTA) as anticoagulant are the 
available analysis methods (25, 77-79). PCR in blood and cerebrospinal fluid (CSF) were 
introduced in the first months of 1992.(80) In 1996, quantitative CMV-PCR testing was 
gradually introduced in the clinical setting. Neither quantitative CMV-PCR assays nor 
quantification of HIV are covered in this thesis, since they were not available at the time. 
	
1.1.9 Treatment of opportunistic infections 
	
As HIV treatment had limited effect, we focused on prophylaxis against PCP and 
toxoplasmosis, as well as screening for and treating OIs and incident opportunistic cancers 
(OC) as soon as the patients presented with symptoms. When patients had been treated for 
OIs such as PCP, toxoplasmosis or Mycobacterium avium complex (MAC) infection, they 
were given lifelong secondary prophylaxis. CMV-infection was treated with foscarnet as 
first-line therapy from 1988 (81, 82) and ganciclovir in addition from 1989. Diagnostic tools 
consisted of blood tests, blood and cell cultures, X-rays, computed tomography (CT) scans, 
magnetic resonance imaging (MRI), as well as biopsies from skin and lymph glands and, 
occasionally, liver and bone marrow. We decided early on that we would not perform brain 
biopsies, as it would pose too big a risk and as the rapid development of PCR testing and 
other CSF analyses would provide more accurate diagnosis (83). 
	
1.1.10. History  of HIV and AIDS diagnosis at Venhälsan 
	
One of the 41 first reported AIDS patients was a Danish citizen (1) and many of us thus 
expected that it was only a matter of time before this new disease would appear in the 
Scandinavian countries. In response to this, an initiative by several physicians, in 
collaboration with the Department of Venerology at Stockholm South General Hospital, The 
Swedish Institute for Infectious Disease Control and The Swedish Association for Sexual 
Equality led to the opening of an outpatient clinic called Venhälsan. Its purpose was to test 
gay men for sexually transmitted infections (STIs) and attempt to detect signs of the new 
immune deficiency syndrome. In the beginning, the clinic was only open in the evenings and 
all tests and examinations could be performed anonymously. All symptoms suspected to be 
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caused by STIs were treated at the clinic as described by Moberg et al (84), but if there were 
signs of AIDS the patients were referred to the Infectious Diseases Clinic at Roslagstull 
Hospital. Several of these first patients were described in Morfelt Månson’s thesis in 1989 
(85). As mentioned above, HIV testing became available in 1985 and, beginning in 1986, 
Venhälsan was open five days a week in order to take care of the increasing number of HIV- 
positive patients. In November 1988, an inpatient ward for AIDS patients was opened; the 
care offered included treatment of all OIs, Kaposi sarcoma, and postoperative care after 
surgery as well as palliative care. The staff included a chef to make as good and nutritious 
food as possible for the patients. Initial treatment of patients with malignant lymphoma was 
in the haematological department. In January 1994, the Maria Regina Hospice began to care 
for some of our most ill patients. At the outset, over 90% of patients with diagnosed AIDS 
died within 2-3 years. 
	
The number of patients with HIV infection that died each year in the Stockholm metropolitan 
area between 1983 and 2014 are shown in Figure 2. The decline in 1988 represents the 
introduction of AZT and the decline after 1996 represents the introduction of ART. 
	
Figure 2 
	
 
	
	
After 1997 most of the patients died of non-AIDS related diseases but still a few patients 
have died of AIDS during these years, mostly if they present with a long-lasting PCP or a 
malignant lymphoma. These patients are called “late testers” or “late presenters”. 
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.A graphic presentation of how AIDS developed in HIV-infected patients before the 
introduction of ART is shown in Figure 3 from Stewart (86). 
	
Figure 3 
	
	
 
	
Figure 3 illustrates clinical symptoms and syndromes developing in cases of HIV infection. 
With decreasing CD4+ count, more serious opportunistic infections and cancers appear. 
	
	
	
	
2 AIMS 
	
The studies in this thesis aimed at investigating: 
	
	
1.   The causes of death in all Venhälsan patients, from diagnosis of the HIV infection to 
death, between 1989 and 1996 
2.   All OIs and OCs in patients who died with CD4+ counts below 100 x 106/mL 
	
3.   The prevalence of CMV encephalitis (CMV-E) and Korsakoffs syndrome (Paper 1) 
	
4.   CMV retinitis (CMV-R) in relation to CMV-E (Paper II) 
	
5.   CMV adrenalitis (CMV-A) and its relation to CMV-R and CMV-E, including 
comparison of CMV assessment by PCR in blood and the Synacthen test 
6.   The correlation between CMV disease and other OIs and OCs (Papers I, II and III) 
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7.   The interaction between CMV, Epstein Barr virus (EBV) and other human herpes 
viruses in a case of anaplastic large cell lymphoma (ALCL) 
	
2.1.1 Materials and Methods 
	
2.1.2 Study cohort 
	
This study cohort was followed prospectively and analysed retrospectively. It consists of 254 
	
HIV-infected patients at Venhälsan who were inpatients and/or outpatients from diagnosis to 
death during1989-1996. When patients had a fever and a CD4+ count of <100 x 106/mL, 
isolation of CMV pp65 antigen (beginning in 1989) or CMV-PCR (beginning in 1992) in 
leukocytes were performed. Patients received toxoplasmosis prophylaxis if their CD4+ cell 
count was <100x106/mL and they were seropositive for toxoplasmosis antigen in blood. From 
1988, patients were given PCP prophylaxis when the CD4+ count was <100x106/mL. 
	
	
As mentioned above, all patients that had been treated for PCP, toxoplasmosis, MAC 
infection, CMV-R or CMV-E received lifelong secondary prophylaxis. All patients were 
given HIV treatment, consisting of AZT from 1989, didanosine (ddI) from 1991 and then in 
combination with zalcitabine (ddC), stavudine (d4T) and/or lamuvidin (3TC) from 1992 and 
onwards. Autopsy, including the brain, was performed if permitted by the patient or his next 
of kin. Patients were diagnosed with AIDS according to the CDC criteria (87), including 
occurrence of OIs (bacterial infections, candidiasis, CMV, toxoplasmosis, PCP, tuberculosis 
(TB), or OCs (Kaposi’s sarcoma, malignant lymphoma, etc) and fever or diarrhoea lasting 
one month or a 10% body weight loss within a month. 
	
2.1.3 Database 
	
The database was constructed as an Excel file. Coded identification numbers were routinely 
given to the Venhälsan patients at the time of the investigation. Data on OIs/OCs in the 
central nervous system (CNS) and results of lumbar puncture (LP), CT, MRI, and 
neurological consultations, as well as demographic data, were compiled in the database. 
CD4+ counts analysed within three months prior to death were also registered. The cohort 
was divided into two groups, the first comprising patients who died with a CD4+ count of 
<100x106/mL after a long disease course with increasing OIs/OCs and gradually diminishing 
	
CD4+ count. The second group consisted of patients who died with a CD4+ count of 
	
>100x106/mL after a short disease course and no apparent OIs/OCs. All data from CNS 
	
autopsy reports, body autopsy reports and patient records were retrieved. 
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2.1.4 Autopsies 
	
Body autopsies were performed according to standard protocols (Rokitansky technique) at the 
Department of Pathology, Karolinska University Hospital in Huddinge. Visceral organs were 
fixed in formaldehyde and paraffin-embedded. CMV, bacterial infections, MAC, 
Cryptococcus, Candida, Toxoplasma, Aspergillus, Cryptosporidium and Pneumocystis carinii 
were assessed microscopically. Non-infectious diseases assessed at autopsy were CNS 
lymphoma, Kaposi’s sarcoma, liver failure, heart failure, cardiovascular disease (CVD) and 
cachexia. 
	
CNS autopsies were performed, according to standard protocols, by Inger Nennesmo, 
pathologist at the Department of Pathology, Karolinska University Hospital in Huddinge. 
Brain biopsies or brain slices were fixed in 4% formaldehyde and paraffin-embedded for 2 
weeks to 2 months (to reduce infectivity). The brain was sectioned in the coronal plane. 
Tissue samples from frontal, temporal and occipital cortex; medulla oblongata; pons; 
midbrain; cerebellum; hippocampus; basal ganglia; thalamus and white matter were collected 
and analysed. Macroscopic focal lesions were sampled for histological analysis. Each tissue 
was stained with haematoxylin-eosin and the white matter was stained with Luxol fast blue. 
Basal ganglia, caudate nucleus, mesencephalon, pons, medulla oblongata and cerebellum 
were also examined macroscopically. 
	
Microscopic examination, immunohistochemistry (IHC) and in situ hybridization (ISH) were 
performed on each tissue sample that was stained with haematoxylin-eosin for diagnosis of 
OIs, OCs and HIV-E. Special histochemical staining (Periodic acid-Shiff, Gomori-Grocott, 
Ziehl-Neelsen, Gram staining, Giemsa) was performed if bacterial, fungal or MAC infections 
were suspected. 
	
CMV, lymphoma and HIV were routinely tested by IHC, performed with monoclonal 
antibodies against CMV (monoclonal antibody CCH2), HIV (anti-p24 antibody) and B-cells 
(monoclonal antibody L26 against CD20). Toxoplasma and syphilis infection were identified 
with polyclonal antiserum for IHC. CMV, JC virus (named after the first patient)-DNA and 
EBV-DNA were also confirmed by ISH if suspected in the brain. JC-virus is the cause 
progressive multifocal leukoencephalopathy (PML). 
	
2.1.5 Lumbar puncture and cerebrospinal fluid,  samples and analysis 
	
CSF was sampled when patients complained of headache and fever and no other cause could 
be found. LP was also done if patients had neurological symptoms such as seizures, memory 
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loss and confusion, especially when the CD4+ count was <50x106/mL. LP was 
contraindicated in patients showing symptoms of high intracranial pressure. 
	
If LP was performed, the analyses included number of cells, glucose, proteins, cytology, 
bacterial culture, mycobacterial culture, Cryptococcus antigen, CMV-, EBV-, and JC-PCR, 
Toxoplasma gondii antigen and syphilis (Wassermann reaction). 
	
2.1.6 Diagnosis of adrenal insufficiency with the Synacthen  test 
	
In patients with CD4 counts <100x106/mL and clinically suspected adrenal insufficiency a 
Synacthen test was performed. Several patients were tested at more than one occasion. The 
Synacthen test in our hands was the first pathological test obtained for each patient. The 
cortisone levels in blood were measured before injection of Synacthen, and 30 and 60 
minutes thereafter. Interpretation of the test is basal and/or stimulated plasma concentration 
of cortisone above 500 nmol/L- standard level - is considered normal and an increase of 200 
nmol/L at 30 or 60 minutes after stimulation is also considered to reflect normally 
functioning adrenal glands.(88, 89) A higher basal and/or stimulated level of 700 nmol/L - 
modified level - for normal response to ACTH has been used as recommended by Cooper and 
Henzen (90, 91). Cortone treatment was given to all patients with pathological Synacthen test 
at the standard level. 
	
2.1.7 Computed  tomography and magnetic  resonance  imagining 
	
CT or MRI was performed if patients had neurological symptoms or if OIs/OCs in the brain 
were suspected. CT/MRI findings were retrieved from medical records. 
	
2.1.8 Clinical  examination 
	
Neurological examination was performed on patients with symptoms from the central and/or 
peripheral nervous system by Ritva Pirskanen-Matell, neurologist at the Department of 
Neurology, Stockholm South General Hospital. Data was retrieved from medical records. 
	
The neurological examinations assessed the cranial nerves, sensory and motor systems. The 
following cognitive tests were performed: orientation, talking, reading, writing, calculating, 
drawing a face, copying a three-dimensional drawing, ability to separate left from right, 
ability to understand abstract meanings, gnosis and praxis. Memory examination included 
repeating six numbers and the short-memory test included remembering five items after three 
minutes and re-reporting a text after reading it. The long-term memory test was to recall what 
had happened the preceding year. To differentiate HIV-E from other causes of encephalitis, 
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the finger tapping test, verbal fluency, connecting consecutive numbers, connecting 
consecutive numbers and letters and digit symbol tests were performed. 
	
Ophthalmological examination was performed by an experienced ophthalmologist 
specialized in retinal pathology. 
	
2.1.9 Treatment of opportunistic infections 
	
The different OIs were treated according to national guidelines at the time of the study. 
	
	
2.1.10 Statistical analysis 
	
The IBM Statistical Package of Software Science (SPSS) 23 was used for analysis of the 
means and standard deviations. Calculations were undertaken with Fisher´s two-tailed exact 
test. The Mc-Nemar’s test was used to analyse differences between two CMV methods in 
Paper I. 
	
2.1.11 Ethical considerations 
	
The study was approved by the Ethics Committee at the Karolinska Institute, Stockholm (Dnr 
	
168/01) 
	
	
3 RESULTS AND DISCUSSION 
	
	
	
	
Table one shows all the patients in the cohort. All were males and from the Stockholm area. 
Median age of diagnosis of HIV was median 35 years (range 23-65), Death with CD+ counts 
of > 100 x 106/mL was 45 years (31-65) and death with CD4+ counts < 100 x 106/mL was 42 
years (28-73) 
	
Table 1 Total cohort 
	
	
	
Patients that died with CD4 + counts < 100 x 106/mL 
	
219 
	
Patients that died with CD4+ counts > 100 x 106/mL 
	
23 
	
Patients not eligible for the cohort or lost to follow-up 
	
12 
	
Total 
	
254 
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Table 2 shows the causes of death in the smaller group of patients with a better preserved 
immune system. 
	
 Table 2. Causes of death in patients with CD4+ counts > 100 x 106/mL   
	
Diagnosis No. of patients No. of patients with 
alcohol as contributing 
	 factor to death 
	
Cardiomyopathy 
	
5 
	
5 
	
Suicide 
	
5 
	
5 
	
Cancer with metastases 
	
3 
	
0 
	
Malignant lymphoma 
	
2 
	
0 
	
Cerebral infarction 
	
2 
	
0 
	
Sudden cardiac death 
	
2 
	
0 
	
Dissecting aortic aneurysm 
	
1 
	
1 
	
Encephalitis of unknown cause 
	
1 
	
0 
	
Hypoglycaemic coma 
	
1 
	
1 
	
Accident 
	
1 
	
0 
	
Total 
	
23 
	
12 
	
	
	
	
And Table 3 shows causes of death in the patients with severe immune deficiency. 
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Table 3. Causes of death in patients that died with CD4+ counts < 100 x 106/mL n=219 
	
Cause of death No. of 
patients 
No. of CMV-PCR+ 
patients 
	
CMV disease 
	
106 
	
104 
	
MAC infection 
	
58 
	
54 
	
Kaposi’s sarcoma 
	
49 
	
46 
	
Toxoplasmosis 
	
29 
	
20 
	
Malignant lymphoma 
	
22 
	
22 
	
CNS lymphoma 
	
20 
	
19 
	
Cardiovascular disease 
	
12 
	
11 
	
PCP 
	
11 
	
10 
	
Progressive multifocal 
leukoencephalopathy (PML) 
	
11 
	
5 
	
Cryptosporidium infection 
	
9 
	
8 
	
Suicide 
	
5 
	
4 
	
Possible adverse reaction to drugs or 
unknown factor 
	
5 
	
5 
	
HIV encephalitis 
	
4 
	
2 
	
Cryptococcal meningitis 
	
3 
	
3 
	
Other cancers 
	
3 
	
3 
	
HIV wasting 
	
2 
	
1 
	
Cysticercosis 
	
1 
	
0 
	
Herpes simplex encephalitis? 
	
1 
	
1 
	
Aspergillus pneumonia 
	
1 
	
1 
	
Pulmonary tuberculosis 
	
1 
	
1 
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In the table, all patients with suspected CMV-disease are included, many died of CMV-E. If 
not diagnosed by a neurologist, they were not included in the Paper I, II and III. 
	
Table 4. CMV infections in HIV-infected patients who died with CD4+ counts < 100 x 
	
106/mL 
	
	
	
CMV manifestation 
	
n 
	
CMV-PCR positive 
	
187 
	
CMV retinitis 
	
84 
	
CMV encephalitis 
	
65 
	
CMV adrenalitis 
	
41 
	
CMV in the gastrointestinal tract 
	
21 
	
CMV colitis 
	
13 
	
CMV esophagitis 
	
5 
	
CMV gastritis and/or duodenitis 
	
3 
	
	
	
	
CMV-E, CMV-R and CMV-A will be described in Paper I, II and III. 
	
	
3.1.1 CMV-infection in the gastrointestinal tract 
	
Eight of the patients with CMV colitis have been reported by Söderlund et al.(92) These 
patients underwent surgery, four hemicolectomy or four iliocecal resection with good results 
and no sequelae in spite of their severe immune deficiency. Of the 21 patients with CMV in 
the gastrointestinal tract three died of PCP, one of toxoplasmosis, one of cryptosporidiosis, 
and one of K S and pneumonia not long after diagnosis of CMV-disease. 
	
Of the last 15 patients nine got CMV-R and nine CMV-E. Thus, the course of the CMV- 
reactivation in these patients was first diagnoses by CMV-PCR in the blood, then 
gastrointestinal CMV within one to six months and finally CMV-R and CMV-E within 18 
months after the gastrointestinal CMV. Most of these patients got treatment with foscarnet in 
courses of seven days every 42 days (six weeks) but that did not prevent development of 
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CMV-A, E and R, however it might have delayed the development of the late manifestations 
of CMV. 
	
3.1.2 CMV in the blood 
	
Table 5. Blood parameters at the first positive CMV-antigen or CMV-PCR test, n = 187 
	
	
	
	
	
	
Test Median (range) 
	
	
Haemoglobin, g/L 113 (70-157) 
	
	
White blood count 109/mL 3,2 (1,0-23,80) 
	
	
Absolute neutrophil count, 109/mL 1,9 (0-9.3) 
	
	
Platelets, 1012/mL 170 (13-606) 
	
	
CD4+ count, 106/mL 20 (1-220) 
	
	
CD8+ count, 106/mL 430 (20-1750) 
	
	
CD4+/CD8 ratio 0,07 (0,0-0,7) 
	
	
	
	
	
The blood parameters show (as expected) low CD4+ and CD8+ counts and very low 
CD4+/CD8+ ratios when the first sign of CMV infection appeared, Haemoglobin, white 
blood count (WBC) and absolute neutrophile count (ANC) were also low. 
	
At the time of CMV testing, most patients were not taking medications that suppressed bone 
marrow function. These low values are thus probably due to the reactivated CMV infection in 
combination with advanced HIV-infection. AZT can suppress the bone marrow in a few per 
cent of patients, these patients, with the typical AZT related anaemia, were instead given 
another nucleoside analogue. 
	
3.1.3 Causes of death in the whole cohort 
	
In the patients that died with CD4+ counts of > 100 x 106/mL, the primary causes of death 
were cardiovascular disease (CVD) in ten, cancer with metastases in five and suicide in five 
cases. Half of the patients had alcohol problems stated in their medical records. From the 
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beginning of the epidemic, we knew that gay men with alcohol or drug problems were at a 
high risk of becoming HIV-infected. 
	
In the cohort of patients that died with CD4+ counts < 100 x 106/mL, the dominant causes of 
death were CMV disease, MAC infection, malignant lymphoma and Kaposi’s sarcoma. 
	
All but 2% were CMV-seropositive at the study start, which explains the high rates of CMV 
activation and disease in our cohort. Our findings are similar to autopsy studies like Monforte 
(56, 93, 94) MAC is very common in water in the Nordic countries which can explain the 
many MAC infections.(95) Only one patient died from pulmonary TB. Five patients 
presented with TB, four with pulmonary TB and one with colitis. Four were cured from their 
TB infection and survived several years before they died of progressive HIV disease. Four of 
the five contracted the infection in another European country or in the US. Death from PCP 
only occurred in 5% of patients, probably due to effective PCP prophylaxis. Toxoplasmosis is 
not so common in the Swedish population (23% are seropositive) (96) which might explain 
the relatively low incidence in our material. We also gave prophylactic treatment to all 
Toxoplasma-seropositive patients. 
	
It is interesting that there were 5% cardiovascular deaths, of which 92% were CMV-PCR 
positive in blood, indicating CMV reactivation. All patients in this group died outside 
hospital and underwent forensic autopsy, i.e. the presence of CMV in the heart or brain was 
not investigated. CMV is increasingly suspected of contributing to CVD in HIV-negative 
populations.(97, 98) 
	
Five patients had committed suicide and they were all severely ill with several OIs at the 
time. 
	
For a more detailed investigation of CMV role in the course of the HIV infection in these 
patients, we studied CMV-E and the Korsakoff syndrome (Paper I), CMV-E and CMV-R 
(Paper II), CMV-A and the correlation to CMV-PCR in blood, CMV-E and CMV-R (Paper 
III), as well as the consequences of an acute CMV infection in a CMV-seronegative HIV- 
infected patient with a well-preserved immune system (Paper IV). 
	
4 CMV ENCEPHALITIS AND THE KORSAKOFF 
SYNDROME (PAPER I) 
	
In the first study, we investigated why several of our patients contracted Korsakoff syndrome. 
The Wernicke-Korsakoff syndrome was first described in 1881 by Wernicke (99) as an acute 
encephalopathy with global confusion, memory disturbances, ophthalmoplegia, nystagmus 
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and unsteadiness of gait. If the patient is not treated when presenting with these symptoms, 
this condition will develop into a chronic encephalopathy, the so called Korsakoff syndrome, 
characterized by progressive dementia, apathy, confabulation, non-violent psychosis and 
peripheral polyneuropathy. Vitamin B1 (thiamine) deficiency is believed to be the cause of 
Wernicke encephalopathy and it can be reversed by thiamine substitution in large doses. 
	
Victor (99) demonstrated neuropathological lesions around the third and fourth ventricle of 
the brain, especially in the surrounding thalamus, hypothalamus, mammillary bodies and 
olive nuclei. He found necrosis and haemorrhagic lesions in these areas. The affected areas 
also include the Papez circuit or limbic system. The limbic system was first believed to be the 
circuit that controls emotions, but is today considered to be the main circuit for establishing 
memory.(100) 
	
The clinical diagnosis was made by a neurological examination combined with CSF analysis, 
	
	
because CT and MRI has not the sensitivity to diagnose Korsakoff syndrome. Typical 
macroscopic and microscopic signs of CMV infection in Korsakoff syndrome are shown in 
Figures 4 and 5. 
	
To be as certain of the diagnosis as possible, we decided to study only the CMV-E patients 
who had been examined by a neurologist less than six months before death. CSF was taken 
from all patients and CT and MR scans were done in most patients. 
	
4.1.1 Results 
	
	
Half of the 34 patients had Korsakoff syndrome. Autopsy was performed in 24 of the 34 
patients and in 13 of the 17 patients with Korsakoff syndrome. We found CMV infection with 
varying degrees of necrosis and micro nodules around the third and fourth ventricles in all 34 
patients. Furthermore, we also found CMV infection in the hypothalamus and hippocampus 
in all patients and in the mammillary bodies and the olive nuclei in several patients, especially 
the Korsakoff patients. Figure 4 shows a section of the brain and Figure 5 shows typical 
microscopical findings in our patients with CMV-E 
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Figure 4 
	
	
 
	
	
Cross-section of a human brain. The red lines indicate the lining of the third and fourth ventricles. These are 
typical locations for CMV-infected cells. In most patients, there was also CMV infection in other parts of the 
brain. 
	
Figure 5 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Microscopic image of CMV infection in the same area; haematoxylin-eosin staining on the left and Lyxol fast 
blue staining on the right. Typical CMV-infected cells and inflammation are seen in both slides. 
	
We did not observe the haemorrhages and necrosis described by Victor; nor did we see other 
OIs in the same areas, with the exception of toxoplasmosis in some individuals. It seems as if 
the Korsakoff syndrome in these patients is caused by changes in the same areas as described 
by Victor and is part of a more generalised CMV infection in the CNS and the whole body. 
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Our patients often had fever, a slight headache and, in some cases, bizarre psychotic 
symptoms as well. 
	
Table 6. Cerebrospinal fluid findings in 34 patients, at 0-6 months before death. Mean 
	
(range) is shown. 
	
	
	
Mononuclear Polynuclear Protein Glucose CMV-PCR 
cells cells positive 
	
2 (0-82) 
	
0 (0-32) 
	
0,34 (0,2-1,7) 
	
mg/mL 
	
2,4 (0,14-2,9) 
	
mg/mL 
	
25/31 
	
	
	
The findings in CSF, including in patients with very advanced HIV and CMV infections, the 
CSF was often devoid of mononuclear and polynuclear cells and mostly exhibited a normal 
protein pattern. Overall, our results are in accordance with other studies by Sundström et al 
and Hagberg et al (101-104). We found that CMV-PCR was positive in 81% of the samples 
taken. 
	
In Table 7, patients with CMV-E with and without Korsakoff syndrome are listed with their 
OIs, OCs and other intercurrent conditions. Some were heavy alcohol users, as noted in their 
medical records. There were no statistically significant differences between the respective 
occurrence of other OIs or OCs. There were more heavy alcohol users in the Korsakoff group 
but the difference was not statistically significant. CMV-A seems to be more prevalent in the 
CMV-E group without Korsakoff. A diagnosis of CMV-A infers that the patients had been 
given cortisone treatment, which might have had a protective effect on the brain. On the 
other hand, the Korsakoff patients might have had undiagnosed adrenal insufficiency, adding 
to the symptoms of CMV in the brain. An interesting finding is that there was more 
polyneuropathy in the Korsakoff group. Polyneuropathy is a common feature of CMV in HIV 
patients(105). However, the number of patients in this study is small, so it is difficult to draw 
any firm conclusions. 
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Table 7 Intercurrent conditions in patients with CMV encephalitis with and without 
	
Korsakoff syndrome 
	
	
CMV-E 
N=17 
CMV-EK 
N= 17 
Statistical 
significance 
	
P 
	
	
	
Heavy alcohol drinker 1 6 0,078 
	
	
Polyneuropathy 12 2 <0.001 
	
	
CNS OI/OC 
	
	
PML 0 3 NS 
	
	
Toxoplasmosis 0 1 NS 
	
	
CNS lymphoma 1 2 NS 
	
	
Systemic OI/OC 
	
	
Kaposi´s sarcoma 5 3 NS 
	
	
MAC infection 9 10 NS 
	
	
Other CMV disease 16 17 NS 
	
	
CMV-R 16 16 NS 
	
	
CMV-A 15 6 <0.01 
	
	
CMV colitis 0 1 NS 
	
	
p- value derived by Fisher’s exact test (two tailed) 
	
	
Abbreviations: CMV-E: CMV encephalitis; CMV-EK: CMV-E with Korsakoff syndrome; 
OI: opportunistic infection; CNS: central nervous system; OC: opportunistic cancer; PML: 
progressive multifocal leucoencephalopathy; CMV-R: CMV retinitis; CMV-A: CMV 
adrenalitis 
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5 THE CORRELATION BETWEEN CMV RETINITIS AND 
CMV ENCEPHALITIS (PAPER II) 
	
In this study, we investigated all patients with a diagnosis of CMV-R, focusing on the extent 
of the eye infection, the outcome of specific CMV treatment and possible correlations with 
CMV-E diagnosed ante mortem or at autopsy. We also correlated the CMV-R diagnosis to 
other OIs in these patients as well as to patients that did not have CMV-R. CMV-R was 
divided into unilateral and bilateral disease, in order to investigate any difference in therapy 
outcome or late complications. We also investigated whether central or peripheral CMV-R 
influenced the outcome. 
	
We found that CMV-R was the most common CMV manifestation as well as the most 
common OI in our cohort. There was a highly significant correlation between CMV-R, 
CMV-E and CMV-A. There was a lower, but significant, correlation with MAC infection, but 
not with other OIs. There was a statistically significant correlation between patients that did 
not have CMV-R and toxoplasmosis. This might be explained by the fact that many patients 
contract toxoplasmosis at a higher CD4+ count, together with the bad prognosis of 
toxoplasmosis. Thus these patients did not live long enough to get the low CD4+ counts 
where CMV-R develops. There was no statistical difference with regard to response to 
treatment or late complications, such as retinal detachment, central retina destruction or 
CMV-E. Only 50 % had a regression at the first ophthalmological check-up at two- three 
weeks after initiation of treatment. Most patients progressed slowly despite combination 
treatment. A more positive outcome was that vision was maintained in 75%, while only 25% 
totally lost vision (visual acuity < 0.1) in the affected eye. Survival was poor in both groups 
and no statistically significant difference in survival duration was noted between them. In the 
whole group, median survival was 207 days (range 3-817). In the autopsied patients that had 
CMV-E, the CMV-infected cells and CMV antigen were clearly visible despite intensive 
antiviral treatment for CMV for more than half a year. The overall impression was that the 
specific CMV treatment had had a limited effect, in contrast to the CMV treatment effect in 
patients with immunodeficiency from other causes than HIV infection. 
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6 CMV-ADRENALITIS: THE VALUE OF SYNACTHEN 
TESTS AND CMV-PCR IN BLOOD (PAPER III) 
	
In this study, we investigated all patients with a positive CMV-PCR for adrenalitis if they had 
fatigue, hypotension (blood pressure < 100/70 mm Hg), nausea and/or diarrhoea. The adrenal 
glands are shown in Figure 6. They consist of medulla, developed from the ectoderm 
embryological plate (same as the brain), and cortex, derived from the mesodermal 
embryological plate. The cortical cells secrete cortisone, aldosterone and 
dehydroepiandrosterone (DHEA); the medulla cells secrete epinephrine and nor epinephrine. 
All of these hormones are important for survival, but cortisone is the most important because 
insufficient cortisone secretion can be an acute life-threatening condition. Other organs, such 
as the liver, can take over the production of epinephrine and nor-epinephrine, for example, so 
insufficiency of the adrenal medulla will not produce symptoms as fast as insufficiency of the 
cortex. Addison’s disease, first described by Thomas Addison in 1855, is characterized by 
fatigue, hypotension, nausea, diarrhoea and extreme pigmentation of the skin and the lines in 
the palm. The pigmentation is caused by compensatory release of adrenocorticotropic 
hormone (ACTH) and melanocyte-stimulating hormone (MSH) from the pituitary. Classic 
Addison’s disease is most often caused by an autoimmune disorder or by TB. The disease 
develops slowly over several years. Elevated serum potassium and decreased serum sodium 
are typical findings. The author Jane Austen and the American president J.F. Kennedy are 
two famous Addison’s patients. 
	
	
	
 
	
	
	
Figure 6. Adrenal glands, palmar hyper pigmentation 
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The position of the adrenal glands and the adrenal cortex and medulla are shown to the left. 
The typical hyper pigmentation of lines in the palm seen in Addison’s disease is shown to the 
right. 
	
To diagnose adrenalitis a Synacthen test (Figure 7) was performed in these cases. 
Figure 7 Synacthen test 
 
	
	
Figure 7 shows the increase in cortisone levels after injection of Synacthen. The left-hand 
curve shows the standard level values. The modified level would be a line 200 nmol/L above 
the dark blue line in the figure. The right-hand test was not used. 
	
6.1.1 Clinical  symptoms and findings 
	
The majority of the patients had symptoms and therefore thus underwent a Synacthen test. At 
that time, we only treated patients if the Synacthen test was pathological based on the 
standard level. Even if the test was pathological according to only one of the two criteria for 
the standard level definition, treatment was also administered. All patients improved 
dramatically. Seven patients went into a typical Addison´s crisis when medication was 
forgotten or another infection developed rapidly. These patients improved again on increased 
cortisone therapy. 
	
6.1.2 Autopsy findings 
	
Of the 46 investigated patients with CMV-A, 44 had macroscopically atrophic adrenal 
glands, according to the autopsy report. In 41 of the analysed adrenal glands, we discovered 
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typical signs of inflammation, necrosis and atrophy, and typical CMV cells were found in 
most of them. These findings were most prominent in the adrenal medulla but the structure 
of the cortex was also severely damaged (Figure 2 in Paper IV) and replaced by 
inflammation, CMV cells and atrophy. 
	
6.1.3 Clinical  symptoms correlated to other CMV-manifestations 
	
Symptoms of adrenalitis were strongly correlated with positive CMV-PCR in blood p<0.001, 
CMV-A p<0.001, CMV-E (p<0.001) and CMV-R (p<0.01), but not with CMV in the 
gastrointestinal tract (p=0.08). There was a minor significant correlation between CMV-A 
and malignant lymphoma (p=0.03), (we found malignant lymphomas in two of the patients 
with CMV-A) but not with any other OI or OC. Thus, a positive CMV-PCR in blood is a 
good marker of CMV infection in the adrenal glands. 
	
6.1.4 Synacthen  tests 
	
We considered two interpretations of the Synacthen test results in CMV-A. As the patients 
obviously had other OIs, a higher threshold could be applied when interpreting the test results 
(90, 91) have shown that a higher threshold can be applied in patients under stress. The 
higher threshold would also apply to the Synacthen tests that did not quite fulfil the criteria 
with the standard level definition. There was a better correlation between test results and 
CMV-A if the modified level was applied, but we still failed to detect all CMV-A with the 
Synacthen test. Indeed, seven (14%) cases of typical CMV-A had normal Synacthen tests. In 
all the Synacthen tested patients we did not see the typical increase in potassium, decrease in 
sodium or the increased skin pigmentation associated with longstanding adrenalitis. This may 
be because CMV-A seems to develop rapidly within months and is accompanied by other 
CMV manifestations, such as CMV-R and CMV-E. These other CMV-induced diseases may 
obscure the symptoms of CMV-A. Another explanation could be that CMV-A develops so 
rapidly that the patients only contracted minor symptoms of CMV-A before they died of 
CMV-E. 
	
We found a high incidence (91%) of CMV-A, consistent with previous autopsy reports (106). 
In addition only two other OIs (PCP and Kaposi’s sarcoma) were found. They caused minor 
pathology in the adrenal glands and were probably not the cause of the adrenalitis symptoms. 
We also found a very strong correlation between adrenalitis symptoms and reactivation of 
CMV infection, CMV-A, CMV-E and CMV-R. 
	
The correlation between autopsy findings and the Synacthen test results was not very strong, 
but the rapidly developing CMV-A and the fact that we did not examine both adrenal glands 
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microscopically might be two reasons for this. In fact, there have not, to our knowledge, been 
any studies published during the last 50 years, comparing results of Synacthen tests with 
adrenal gland findings at autopsy (Pub med search 2017). 
	
7 ANAPLASTIC LARGE CELL LYMPHOMA, PRIMARY 
CMV-INFECTION, HHV-8 INFECTION AND EBV 
REACTIVATION (PAPER IV) 
	
In our first three studies, we investigated the role of reactivated CMV infection in patients 
with advanced HIV infection. In this paper, we describe another disease caused by a primary 
CMV infection and other human herpes viruses in a patient with an HIV infection and well- 
preserved immune status. 
	
A young man with an HIV infection detected two years earlier, and who was healthy without 
treatment, fell ill with fatigue, fever and enlarged lymph glands and spleen. He was admitted 
to our inpatient unit. Blood tests, including WBC and differential count were performed. 
They revealed lymphocytosis and cells typical for mononucleosis, which might have been 
due to CMV or EBV infection. Blood tests for CMV and EBV were taken. However, the 
patient’s health did not improve. The lymph glands in the neck, axillae and spleen continued 
to increase in size, as did the liver. 
	
Figure 8 Blood differential count image (haematoxylin-eosin staining). 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Red blood cells and enlarged Mackinlay cells are seen in both panels. Such abnormal cells are seen in acute or 
primary CMV and EBV infections and are of T-cell origin (activated CD8 cells). 
	
A malignancy such as lymphoma was suspected. A bone marrow aspirate, a liver biopsy and 
a biopsy from a neck lymph gland were performed. The lymph gland only showed reactive 
inflammation at initial assessment and no lymphoma was found in the liver or bone marrow 
aspirates at that time. Later test results from the blood samples taken at admittance showed 
positive CMV-PCR and the patient was treated with foscarnet, with good effect initially. His 
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fever disappeared and his health improved. Then he suddenly deteriorated and died. Autopsy 
revealed a generalized malignant lymphoma in the lymph glands, spleen, liver and bone 
marrow (Figure 9). The immediate cause of death was adult respiratory distress syndrome 
	
The lymphoma was classified as an adult large cell lymphoma (ALCL). A re-evaluation of the 
lymph node from the neck showed a small focus of the same lymphoma. All blood samples 
taken before and after the lymphoma onset were analysed for CMV, EBV and HIV, since we 
suspected that these viruses might have influenced the lymphoma development. Later, herpes 
simplex virus (HSV) 1 and 2, varicella zoster virus (VZV) and human herpes virus (HHV)-6, 
-7 and -8 assays were added. It emerged that the patient had a latent EBV infection that was 
reactivated by a primary CMV infection. Moreover, he had a HHV-8 infection with rapidly 
increasing HHV-8 and EBV-PCR levels at the same time as the tumour developed. The 
development of IgM antibodies to HHV-8 suggested a primary HHV-8 infection. The strong 
inflammation induced by the primary CMV infection might have activated the carcinogenic 
properties of both EBV and HHV-8, causing the fatal lymphoma. EBV is believed to cause 
most of the lymphomas in HIV patients,(107) and HHV-8 also contributes (108). None of 
them have previously been described in connection with ALCL in AIDS patients. To our 
knowledge this is also the first time that an interaction between three herpes viruses causing a 
malignant lymphoma is described. The other five herpes viruses 
were not activated or believed to be involved in the development of the lymphoma. 
	
	
Figure 9 
	
	
Adult large cell lymphoma cells (magnification x 10, insert x 40) 
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8 CONCLUSIONS 
	
Reactivated CMV infection was the most important OI in this cohort of gay men with HIV 
infection as 87% were CMV-antigen or CMV-PCR positive in blood. Ninety-eight percent of 
them had acquired the CMV infection previously, as determined by serology tests. The most 
important clinical manifestations were CMV-E, CMV-R and CMV-A. This is in contrast to 
most reports on AIDS-patients, which find CMV-retinitis and CMV-colitis to be the most 
common CMV-manifestations. In these reports CMV-A and CMV-E are not systematically 
investigate. 
	
CMV also, in this study, seems to be the most important factor in causing death, often in 
combination with other OIs. 
	
The typical cause of CMV-reactivation is The results of these studies are of importance for 
all HIV patients, irrespective of gender, transmission route of the HIV-infection, as the 
majority of HIV infected patients are co-infected with both viruses. It is also important to 
acknowledge that reactivated CMV infection is mainly manifested in the brain, retina and 
adrenal glands, in contrast to the CMV manifestations in induced immune deficiency during 
chemotherapy for tumours or immunosuppressive therapy after transplantation. One 
explanation for this could be that these two viruses, which both are neurotropic, interact 
differently compared to immune deficiency from different causes. The combination of CMV 
and HIV is considered a significant risk even in HIV patients taking ART both (109). As we 
have shown antiviral treatment for CMV had limited effects in these co-infected patients 
before ART for HIV infection became available. Thus, when CMV is detected in HIV- 
infected patients, ART treatment should begin as soon as possible. The natural history of 
HIV and CMV infection in co-infected patients has thus been described in this cohort of male 
	
HIV patients studied before ART became available. The findings have significance for: 
	
	
1.   All HIV-infected patients with CD4+ counts < 100 x 106/mL 
	
2.   HIV infections discovered late, in so-called late testers 
	
3.   Patients with limited access to HIV treatment 
	
4.   Other patients treated with immunosuppressive therapy, especially those treated with 
anti-T-lymphocyte antibodies 
5.   Bone marrow transplant or solid organ transplant recipients 
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The studies in this thesis also add knowledge concerning the nature CMV - infection: 
	
	
1. Knowledge about the natural course when treatment is not available 
	
	
2. Knowledge about CMV-adrenalitis and its relation to CMV-retinitis and CMV-encephalitis 
	
	
3. Knowledge about the neurotropic nature of CMV in patients co-infected with HIV 
	
	
4. Knowledge about the influence of primary CMV infection on the gamma herpes viruses 
	
	
EBV and HHV-8 in rapidly progressing malignant lymphomas 
	
	
5. Possible contribution to our understanding of the influence of CMV in the aging process 
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9 FUTURE PERSPECTIVES, RESEARCH ON CO- 
INFECTED PATIENTS 
	
In recent years, the focus of CMV research has been on its possible role in arteriosclerosis in 
patients without HIV-infection. Most studies have been based on serology studies, showing 
that people with positive CMV serology carry a higher risk of arteriosclerosis. Furthermore, 
the interaction between HIV and CMV has been recently been highlighted by Gianella et al 
(71, 110). 
	
In these studies patients with reactivation of CMV for shorter periods of time in HIV-patients 
has been investigated. 
	
Many of the patients at Venhälsan that survived after being given ART during 1996-1998 
were CMV-PCR positive in blood and some have also had CMV-R. A few have had CMV-E. 
	
These patients have had a longer lasting CMV-reactivation (for months to a year) as 
measured by CMV-PCR. Thus we are planning a follow-up study of all these patients with 
focus on the late effects of CMV reactivation, including residual symptoms after subclinical 
CMV-E, CMV-A and also arteriosclerosis. We have noted an increased incidence of chronic 
pancreatitis, pancreatic insufficiency as well as gout in many of our patients and will 
investigate if that could be related to longstanding HIV and CMV co-infection. An 
investigation of patients that had had a significant CMV reactivation measured with CMV- 
PCR in blood might provide new information on the interaction between HIV and CMV. 
	
We and others have noticed that 90% of the patients have the CXCR4 virus in the blood 
when they have AIDS-defining diseases (76). It would be interesting to know if it is the 
CXCR4 form that contributes to the development of CMV-infection in these co inthese co- 
infected patients. 
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10 PRACTICAL GUIDELINES FOR DIAGNOSING CMV- 
ADRENALITIS, - ENCEPHALITIS AND -RETINITIS IN 
HIV-INFECTED PATIENTS AND RAPIDLY 
PROGRESSING LYMPHOMAS. 
	
	
	
1.   When a HIV-infected patient has a CD4+ count < 100 x 106/mL, CMV-PCR 
should be analysed in blood. If positive, an ophthalmological examination is 
indicated, as well as a neurological examination, to detect signs of CNS 
involvement. 
2.   If a CMV-retinitis is diagnosed, the possibility of CMV-encephalitis should be 
investigated both by clinical neurological examination and lumbar puncture. A 
Synacthen test should also be performed if the patient has signs of adrenal 
insufficiency. ACTH and aldosterone should be analysed together with the 0 
sample for cortisone. In case of pathological results, continue as in point 4. 
3.  If CMV encephalitis is diagnosed, both CMV and HIV encephalitis should be 
investigated by neurological examination and lumbar puncture, with analysis of 
HIV, CMV, EBV, toxoplasmosis and syphilis antigens. A Synacthen test should 
also be performed. 
4.   If CMV adrenalitis is suspected, a Synacthen test should be performed together 
with ACTH, aldosterone, testosterone and sexual hormone binding protein 
(SHBG) analyses. 
5.   The Synacthen test should be interpreted at the modified level presented in Paper 
	
III. 
	
6.   Do not forget that a patient with HIV and reactivated CMV-infection can have 
more opportunistic infections at the same time. 
7.   If a very rapidly progressing malignant lymphoma in an HIV patient is found, 
blood PCR for CMV, EBV and HHV-8 should be tested and the patient should be 
given initial treatment for CMV with foscarnet or ganciclovir. The patient should 
subsequently be administered chemotherapy appropriate to the type of lymphoma 
and be continuously monitored with PCR tests for virus infection. 
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